Methylphenidate for fatigue in ambulatory men with prostate cancer.

@article{Roth2010MethylphenidateFF,
  title={Methylphenidate for fatigue in ambulatory men with prostate cancer.},
  author={Andrew J. Roth and Christian J. Nelson and Barry Rosenfeld and Howard I. Scher and Susan Slovin and Michael F. Morris and Noelle O'Shea and Gabrielle Arauz and William Breitbart},
  journal={Cancer},
  year={2010},
  volume={116 21},
  pages={
          5102-10
        }
}
BACKGROUND Fatigue is a highly prevalent and clinically significant symptom of advanced prostate cancer. To date, however, there are no published controlled trials of interventions for fatigue in men with prostate cancer. METHODS This 6-week, randomized, double-blind, placebo-controlled design evaluated the efficacy of methylphenidate to treat fatigue in prostate cancer patients. Inclusion criteria included men with advanced prostate cancer and the presence of moderate to severe fatigue… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 25 CITATIONS

A novel infusible botanically-derived drug, PG2, for cancer-related fatigue: a phase II double-blind, randomized placebo-controlled study.

  • Clinical and investigative medicine. Medecine clinique et experimentale
  • 2012
VIEW 6 EXCERPTS
CITES BACKGROUND, RESULTS & METHODS
HIGHLY INFLUENCED

Fatigue beim metastasierten Prostatakarzinom

  • Uro-News
  • 2016
VIEW 1 EXCERPT
CITES BACKGROUND